• 1. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 2. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 3. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 4. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 5. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832

Recent Advances in the Study of 6-(Difluoromethoxy)pyridin-2-ylmethanamine (CAS: 2044834-22-0)

6-(Difluoromethoxy)pyridin-2-ylmethanamine (CAS: 2044834-22-0) is a novel chemical compound that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique difluoromethoxy and pyridinylmethanamine moieties, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and potential as a key intermediate or active pharmaceutical ingredient (API) in drug development.

The synthesis of 6-(difluoromethoxy)pyridin-2-ylmethanamine has been optimized to achieve high yields and purity, which is critical for its application in medicinal chemistry. Researchers have employed advanced techniques such as palladium-catalyzed cross-coupling reactions and fluorination strategies to introduce the difluoromethoxy group, ensuring the compound's structural integrity and functional efficacy. These synthetic routes have been documented in recent patents and peer-reviewed journals, highlighting the compound's growing importance in the pharmaceutical industry.

Pharmacological studies have revealed that 6-(difluoromethoxy)pyridin-2-ylmethanamine exhibits notable bioactivity, particularly in the modulation of specific enzyme systems and receptor interactions. For instance, preliminary in vitro and in vivo assays suggest its potential as a modulator of central nervous system (CNS) targets, making it a candidate for the treatment of neurological disorders. Additionally, its metabolic stability and pharmacokinetic profile have been investigated, with results indicating favorable absorption and distribution properties.

In the context of drug discovery, 6-(difluoromethoxy)pyridin-2-ylmethanamine has been explored as a building block for the development of novel small-molecule therapeutics. Its structural features allow for versatile derivatization, enabling the creation of analogs with enhanced potency and selectivity. Recent collaborations between academic institutions and pharmaceutical companies have accelerated the exploration of this compound's therapeutic potential, with several derivatives currently undergoing preclinical evaluation.

Despite these advancements, challenges remain in the full characterization of 6-(difluoromethoxy)pyridin-2-ylmethanamine's mechanism of action and long-term safety profile. Ongoing research aims to address these gaps through comprehensive toxicological studies and mechanistic investigations. The compound's potential for off-target effects and its interaction with biological systems are areas of active inquiry, with findings expected to inform future clinical development.

In conclusion, 6-(difluoromethoxy)pyridin-2-ylmethanamine (CAS: 2044834-22-0) represents a promising candidate in the realm of chemical biology and pharmaceutical research. Its synthetic accessibility, pharmacological properties, and versatility as a molecular scaffold underscore its value in drug discovery. As research progresses, this compound is poised to contribute significantly to the development of innovative therapeutics, particularly in areas of unmet medical need.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)